Product Information
MESALAMINE DR 1.2 GM TABLET is a generic product labeled by Chartwell RX LLC, priced at $0.7809 per EA under NDC 62135071460. Its NADAC has been published 153 times since Nov 1, 2023.
FDA first approved this application on May 12, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1.2 g/1
Manufacturer
Chartwell RX LLCNDC
62135071460
Classification
Generic
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MESALAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA217337FDA Approved
5/12/2023
TE Code
AB
On Market Since
6/3/2023
Pharmacological Classes
Price Statistics
The NADAC for MESALAMINE DR 1.2 GM TABLET has been published 153 times since Nov 1, 2023, and over the history we have for it it has declined 59.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7809 per EA |
|---|---|
| All-time high | $2.0543 (Feb 14, 2024) |
| All-time low | $0.7809 (Sep 23, 2026) |
| 52-week high | $1.0132 |
| 52-week low | $0.7809 |
| Median price | $1.1318 |
| Average price | $1.1994 |
| Largest weekly change | +45.9% (Aug 21, 2024) |
| Weeks tracked | 153 |
| Tracking since | Nov 1, 2023 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mesalamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminosalicylate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MESALAMINE DR 1.2 GM TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MESALAMINE DR 1.2 GM TABLET, manufactured by Chartwell RX LLC, is $0.7809 per EA (NDC 62135071460), effective Sep 30, 2026.
How has the price of MESALAMINE DR 1.2 GM TABLET changed over time?
Over the history we have for it, the NADAC for MESALAMINE DR 1.2 GM TABLET has declined 59.7%. It has been tracked across 153 weekly CMS publications since Nov 1, 2023.
What are the highest and lowest recorded NADAC prices for MESALAMINE DR 1.2 GM TABLET?
Since Nov 1, 2023, the NADAC for MESALAMINE DR 1.2 GM TABLET has ranged from a low of $0.7809 (Sep 23, 2026) to a high of $2.0543 (Feb 14, 2024), with a median of $1.1318 per EA.
Are there cheaper alternatives to MESALAMINE DR 1.2 GM TABLET?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as MESALAMINE DR 1.2 GM TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures MESALAMINE DR 1.2 GM TABLET?
MESALAMINE DR 1.2 GM TABLET (NDC 62135071460) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.